Research Analysts Offer Predictions for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Adaptimmune Therapeutics in a research report issued on Tuesday, March 25th. Leerink Partnrs analyst J. Chang forecasts that the biotechnology company will post earnings of ($0.10) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.

A number of other equities analysts have also recently commented on the stock. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday, March 21st. StockNews.com started coverage on shares of Adaptimmune Therapeutics in a research report on Friday, March 21st. They set a “buy” rating on the stock. Wells Fargo & Company reduced their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. Finally, Guggenheim lowered their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Trading Down 4.4 %

NASDAQ:ADAP opened at $0.22 on Friday. The company has a market capitalization of $56.29 million, a PE ratio of -1.00 and a beta of 2.52. Adaptimmune Therapeutics has a 52-week low of $0.22 and a 52-week high of $1.65. The stock’s 50 day moving average price is $0.51 and its 200 day moving average price is $0.68. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. increased its position in Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares in the last quarter. Two Sigma Investments LP grew its holdings in Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC raised its position in Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 94,623 shares during the period. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.